Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTV0DK)

• Drug Name: IM1240 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Preclinical	[1]

• Cross-matching ID: TTD Drug ID: DMTV0DK

Molecule-Related Drug Atlas

Drug(s) Targeting Oncotrophoblast glycoprotein 5T4 (TPBG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TroVax	DMHDNK0	Prostate cancer	2C82.0	Phase 3	[2]
Naptumomab estafenatox	DM901ZW	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[3]
CV-9201	DMCPZYT	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[4]
GEN1044	DMQ9317	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
PF-06263507	DM5KBDY	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
Anatumomab mafenatox	DMMLDG8	Breast cancer	2C60-2C65	Terminated	[7]

Drug(s) Targeting NKG2-A/B-activating NK receptor (NKG2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NN8765	DMCFPBE	Rheumatoid arthritis	FA20	Phase 2	[8]
Monalizumab	DMG7XHE	Chronic lymphocytic leukaemia	2A82.0	Phase 1/2	[9]
BMS-986315	DMTEY1L	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[10]

Drug(s) Targeting T-cell surface glycoprotein CD3 (CD3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Blinatumomab	DMGECIJ	Acute lymphoblastic leukaemia	2A85	Approved	[11]
Mosunetuzumab	DM15ZIB	Follicular lymphoma	2A80	Approved	[12]
Epcoritamab	DMEX86V	Diffuse large B-cell lymphoma	2A81	Approved	[13]
Talquetamab	DMXRENI	Multiple myeloma	2A83	Approved	[14]
Elranatamab	DMG1MW2	Multiple myeloma	2A83	Approved	[15]
Nivatrotamab	DMAOUZV	Small-cell lung cancer	2C25.Y	Phase 2	[16]
Otelixizumab	DMFNDBC	Type-1 diabetes	5A10	Phase 2	[17]
Plamotamab	DMOV28A	Diffuse large B-cell lymphoma	2A81	Phase 2	[18]
Odronextamab	DMP6NVV	B-cell non-hodgkin lymphoma	2B33.5	Phase 2	[19]
Tarlatamab	DME33OU	Small-cell lung cancer	2C25.Y	Phase 2	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
NKG2-A/B-activating NK receptor (NKG2A)	TTC4IMS	NKG2A_HUMAN	Not Available	[1]
Oncotrophoblast glycoprotein 5T4 (TPBG)	TT70MLA	TPBG_HUMAN	Not Available	[1]
T-cell surface glycoprotein CD3 (CD3)	TTUN7MC	NOUNIPROTAC	Not Available	[1]

References

• [1] Clinical pipeline report, company report or official report of Purple
• [2] Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res. 2010 Nov 15;16(22):5539-47.
• [3] Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin. Curr Oncol Rep. 2014 Feb;16(2):370.
• [4] National Cancer Institute Drug Dictionary (drug id 648549).
• [5] Clinical pipeline report, company report or official report of AbbVie.
• [6] National Cancer Institute Drug Dictionary (drug id 751006).
• [7] A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer. 2007 Feb 26;96(4):567-74.
• [8] Handbook of Therapeutic Antibodies. 2014. 1. Page(1098).
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] ClinicalTrials.gov (NCT04349267) Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors. U.S. National Institutes of Health.
• [11] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [12] Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
• [13] Clinical pipeline report, company report or official report of Genmab.
• [14] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
• [15] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
• [16] Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
• [17] Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
• [18] Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
• [19] Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
• [20] Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.